Vera Therapeutics, Inc.
VERA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $564 | $563 | $0 | $0 |
| Gross Profit | -$564 | -$563 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $56,344 | $58,076 | $41,278 | $33,347 |
| G&A Expenses | $0 | $21,946 | $14,580 | $15,567 |
| SG&A Expenses | $27,024 | $21,946 | $15,916 | $15,567 |
| Sales & Mktg Exp. | $0 | $0 | $1,336 | $0 |
| Other Operating Expenses | $0 | -$444 | $0 | $0 |
| Operating Expenses | $83,368 | $79,578 | $57,194 | $48,914 |
| Operating Income | -$83,932 | -$80,141 | -$57,194 | -$48,914 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,639 | $3,610 | $5,500 | $5,490 |
| Pre-Tax Income | -$80,293 | -$76,531 | -$51,694 | -$43,424 |
| Tax Expense | – | $0 | $0 | $1 |
| Net Income | -$80,293 | -$76,531 | -$51,694 | -$43,425 |
| % Margin | – | – | – | – |
| EPS | -1.26 | -1.2 | -0.81 | -0.85 |
| % Growth | -5% | -48.1% | 4.7% | – |
| EPS Diluted | -1.26 | -1.2 | -0.81 | -0.85 |
| Weighted Avg Shares Out | 63,847 | 63,789 | 63,672 | 54,898 |
| Weighted Avg Shares Out Dil | 63,847 | 63,789 | 63,672 | 54,898 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,736 | $6,320 | $6,906 | $6,663 |
| Interest Expense | $1,960 | $1,874 | $1,792 | $1,871 |
| Depreciation & Amortization | $564 | $563 | $85 | $55 |
| EBITDA | -$77,769 | -$74,094 | -$49,817 | -$41,498 |
| % Margin | – | – | – | – |